Needham Reiterates Buy on KalVista Pharmaceuticals, Maintains $28 Price Target

Benzinga · 2d ago
Needham analyst Serge Belanger reiterates KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy and maintains $28 price target.